And PWC thought the buyer would want the contracts for those non-assertion rights, even prepared a motion to have them assigned to that buyer, providing they'd pay the royalties that were due for the time the plant ran in 2018:
Problem was, the buyer changed his mind, and elected not to take them, could have had them for just ponying up the $409k in royalties. Guess those contracts aren't such a windfall after all.
The NOL's are worthless, BioAmber has no operations, and cannot be purchased to use the NOL's.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.